AIM: To identify severe adverse events (SAEs) leading to treatment discontinuation that occur during antiviral therapy in hepatitis C virus (HCV)-infected cirrhotic patients. METHODS: We identified all the articles published prior to December 2011 in the PubMed, Medline, Lilacs, Scopus, Ovid, EMBASE, Cochrane and Medscape databases that presented these data in cirrhotic patients. These studies evaluated the rate of SAEs leading to discontinuation of standard care treatment: Pegylated interferon (PegIFN) alpha 2a (135-180 μg/wk) or PegIFN alpha 2b (1 or 1.5 μg/kg per week) and ribavirin (800-1200 mg/d). Patients with genotype 1 + 4 underwent treatment for 48 wk, whereas those with genotypes 2 + 3 were treated for 24 wk. RESULTS: We included 17 papers in this review, comprising of 1133 patients. Treatment was discontinued due to SAEs in 14.5% of the patients. The most common SAEs were: severe thrombocytopenia and/or neutropenia (23.2%), psychiatric disorders (15.5%), decompensation of liver cirrhosis (12.1%) and severe anemia (11.2%). The proportion of patients who needed to discontinue their therapy due to SAEs was significantly higher in patients with Child-Pugh class B and C vs those with Child-Pugh class A: 22% vs 11.4% (P = 0.003). A similar discontinuation rate was found in cirrhotic patients treated with PegIFN alpha 2a and those treated with PegIFN alpha 2b, in combination with ribavirin: 14.2% vs 13.7% (P = 0.96). The overall sustained virological response rate in cirrhotic patients was 37% (95%CI: 33.5-43.1) but was significantly lower in patients with genotype 1 + 4 than in those with genotype 2 + 3: 20.5% (95%CI: 17.9-24.8) vs 56.5% (95%CI: 51.5-63.2), (P < 0.0001). CONCLUSION: Fourteen point five percent of HCV cirrhotic patients treated with PegIFN and ribavirin needed early discontinuation of therapy due to SAEs, the most common cause being hematological disorders.
AIM: To identify severe adverse events (SAEs) leading to treatment discontinuation that occur during antiviral therapy in hepatitis C virus (HCV)-infected cirrhoticpatients. METHODS: We identified all the articles published prior to December 2011 in the PubMed, Medline, Lilacs, Scopus, Ovid, EMBASE, Cochrane and Medscape databases that presented these data in cirrhotic patients. These studies evaluated the rate of SAEs leading to discontinuation of standard care treatment: Pegylated interferon (PegIFN) alpha 2a (135-180 μg/wk) or PegIFN alpha 2b (1 or 1.5 μg/kg per week) and ribavirin (800-1200 mg/d). Patients with genotype 1 + 4 underwent treatment for 48 wk, whereas those with genotypes 2 + 3 were treated for 24 wk. RESULTS: We included 17 papers in this review, comprising of 1133 patients. Treatment was discontinued due to SAEs in 14.5% of the patients. The most common SAEs were: severe thrombocytopenia and/or neutropenia (23.2%), psychiatric disorders (15.5%), decompensation of liver cirrhosis (12.1%) and severe anemia (11.2%). The proportion of patients who needed to discontinue their therapy due to SAEs was significantly higher in patients with Child-Pugh class B and C vs those with Child-Pugh class A: 22% vs 11.4% (P = 0.003). A similar discontinuation rate was found in cirrhotic patients treated with PegIFN alpha 2a and those treated with PegIFN alpha 2b, in combination with ribavirin: 14.2% vs 13.7% (P = 0.96). The overall sustained virological response rate in cirrhotic patients was 37% (95%CI: 33.5-43.1) but was significantly lower in patients with genotype 1 + 4 than in those with genotype 2 + 3: 20.5% (95%CI: 17.9-24.8) vs 56.5% (95%CI: 51.5-63.2), (P < 0.0001). CONCLUSION: Fourteen point five percent of HCV cirrhoticpatients treated with PegIFN and ribavirin needed early discontinuation of therapy due to SAEs, the most common cause being hematological disorders.
Authors: M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht Journal: Lancet Date: 2001-09-22 Impact factor: 79.321
Authors: B E Annicchiarico; M Siciliano; A W Avolio; G Caracciolo; A Gasbarrini; S Agnes; M Castagneto Journal: Transplant Proc Date: 2008 Jul-Aug Impact factor: 1.066
Authors: Jose A Carrión; Eva Martínez-Bauer; Gonzalo Crespo; Santseharay Ramírez; Sofia Pérez-del-Pulgar; Juan Carlos García-Valdecasas; Miquel Navasa; Xavier Forns Journal: J Hepatol Date: 2008-12-29 Impact factor: 25.083
Authors: Eliya Syed; Nogol Rahbin; Ola Weiland; Tony Carlsson; Antti Oksanen; Markus Birk; Loa Davidsdottir; Karin Hagen; Rolf Hultcrantz; Soo Aleman Journal: Scand J Gastroenterol Date: 2008 Impact factor: 2.423
Authors: Stephanos J Hadziyannis; Hoel Sette; Timothy R Morgan; Vijayan Balan; Moises Diago; Patrick Marcellin; Giuliano Ramadori; Henry Bodenheimer; David Bernstein; Mario Rizzetto; Stefan Zeuzem; Paul J Pockros; Amy Lin; Andrew M Ackrill Journal: Ann Intern Med Date: 2004-03-02 Impact factor: 25.391
Authors: Partha K Chandra; Feyza Gunduz; Sidhartha Hazari; Ramazan Kurt; Rajesh Panigrahi; Bret Poat; David Bruce; Ari J Cohen; Humberto E Bohorquez; Humberto E Behorquez; Ian Carmody; George Loss; Luis A Balart; Tong Wu; Srikanta Dash Journal: PLoS One Date: 2014-09-29 Impact factor: 3.240
Authors: Louis S Matza; Sandhya J Sapra; John F Dillon; Anupama Kalsekar; Evan W Davies; Mary K Devine; Jessica B Jordan; Amanda S Landrian; David H Feeny Journal: Eur J Health Econ Date: 2014-12-07
Authors: Aline Vitali Grando; Paulo Roberto Abrão Ferreira; Mário Guimarães Pessôa; Daniel Ferraz de Campos Mazo; Carlos Eduardo Brandão-Mello; Tânia Reuter; Ana de Lourdes Candolo Martinelli; Mário Peribanez Gonzalez; Ana Catharina Seixas-Santos Nastri; Aléia Faustina Campos; Max Igor Banks Ferreira Lopes; José David Urbaez Brito; Maria Cássia Mendes-Corrêa Journal: Rev Inst Med Trop Sao Paulo Date: 2017-11-06 Impact factor: 1.846